Can your genes predict prostate Cancer's next move?
NCT ID NCT05810467
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 200 men with low-risk prostate cancer who are on active surveillance (monitoring instead of immediate treatment). Researchers want to see if men with a higher genetic risk for prostate cancer are more likely to have their cancer progress over time. The goal is to better understand who can safely stay on surveillance and who may need treatment sooner.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict which men with low-risk prostate cancer can safely avoid treatment and which need closer monitoring.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve outcomes for participants, and results may take years to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2023
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
* Control group (i.e., no known high PrCa risk): 100 men * Men at genetically higher PrCa risk: 100 men
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Men ≥18 years old under the care of an Active Surveillance clinic. * Known diagnosis of PrCa, deemed suitable for Active surveillance at multi-disciplinary meeting (MDT). * Men at genetically higher PrCa risk who are either: (1) Men of any ancestry with a positive family history of PrCa defined as: * Having a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years * Having two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years * Having three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age Or (2) Men of Black African or Black African-Caribbean ancestry defined as: * Both parents and all 4 grandparents from that origin Or (3) Men of any ancestry with a pathogenic mutation in a gene thought to cause a higher risk of prostate cancer: (including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in appendix A) Or (4) Men of any ancestry with a high genetic risk (common and/or rare variants) for PrCa resulting in a RR of ≥2 of PrCa * Men of any ancestry with no known high risk genetic factors who have been diagnosed with low grade PrCa and deemed suitable for Active Surveillance at multi-disciplinary meeting (control group) as defined in the 4 criteria above. * Who performance status 0-2 * Absence of any psychological, familial, sociological, or geographical situation potentially hampering compliance with the study protocol and follow-up schedule. Exclusion Criteria * No PrCa diagnosis * PrCa diagnosis that is not deemed suitable for active surveillance at multi-disciplinary meeting * Any significant psychological conditions that may be worsened or exacerbated by participation in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institute of Cancer Research and Royal Marsden Hospital
RECRUITINGSutton, Surrey, SM2 5PT, United Kingdom
-
North Bristol NHS Trust
NOT_YET_RECRUITINGBristol, BS10 5NB, United Kingdom
-
The Royal Marsden Hospital
RECRUITINGLondon, SW3 6JJ, United Kingdom
-
The Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive missile aims at prostate cancer that spread
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can a new PET tracer spot hidden prostate cancer spread?
- Can a gel cushion shield the rectum during prostate radiation?
- A scanner in the operating room could show surgeons exactly where prostate cancer remains